To read the full story, subscribe or sign in.

Arrivent, Alphamab ink $615.5M multitarget ADC partnership

June 6, 2024

Arrivent Biopharma Inc. and Jiangsu Alphamab Biopharmaceuticals Co. Ltd. have signed a development deal that leverages Alphamab’s antibody-drug conjugate (ADC) research and discovery platform and could bring Alphamab up to $615.5 million.

BioWorld Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific U.S.

Today's news in brief

BioWorld

BioWorld briefs for Nov. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 17, 2025.

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...